— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...
In the 12-month period ending in December 2022, over 79,000 people in the U.S. were reported to have died of an opioid overdose, of whi...
“Resolian merges expertise from Alliance Pharma and Drug Development Solutions — two leading providers of bioanalysis and analytical sciences &...
"We are very pleased to achieve full patient enrollment in Asia ahead of schedule, which brings Everest an important step closer to offering etrasimod to p...
"Hot flashes as a result of menopause can be a serious physical burden on women and impact their quality of life," said Janet Maynard, M.D., M.H.S., direct...
Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039. The allowed claims cover MN...
Veeva Systems (NYSE: VEEV) today announced that Sanofi is implementing Veeva Vault QMS and Veeva Vault QualityDocs to modernize quality management across t...
This is the seventh NMPA-approved indication of TYVYT® (sintilimab injection). The first six indications of TYVYT® (sintilimab injection) are inclu...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA)...
“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expan...
Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients...
Akorn Operating Company LLC has filed Chapter 7 bankruptcy on February 23, 2023. In connection with that filing, the company has ceased and shutdow...
PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce the establishment of a 50:50 joint venture, "Cortexa", with Austr...
© 2025 Biopharma Boardroom. All Rights Reserved.
